CIK 0001396814 · Large accelerated filer
Pacira BioSciences, Inc.
Sign in to watch- Ticker
- PCRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 510619477
- Phone
- 650-242-8052
- Business address
- 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE, CA, 94005
- Former names
- Pacira Pharmaceuticals, Inc., PACIRA INC, Blue Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $288,539
- in 2 filings, $289K under 10b5-1 plans
Net −$288,539. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-10 | Brege Laura Director | Grant or award · Stock Option (Right to Buy) | +10,891 | 10,891 | ||
| 2026-06-04 | WILLIAMS KRISTEN Chief Administrative Officer | Sale 10b5-1 | −10,259 | $22.27 | $228K | 167,062 |
| 2026-06-03 | RIKER LAUREN Senior Vice President, Finance | Shares withheld for taxes | −3,187 | $22.32 | $71K | 68,399.24 |
| 2026-06-03 | SLONIN JONATHAN Chief Medical Officer | Shares withheld for taxes | −4,728 | $22.32 | $106K | 218,912.18 |
| 2026-06-03 | WILLIAMS KRISTEN Chief Administrative Officer | Shares withheld for taxes 10b5-1 | −8,528 | $22.32 | $190K | 177,321 |
| 2026-04-23 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 | +12,941 | $16.45 | $213K | 118,282 |
| 2026-04-23 | Cross Shawn Chief Financial Officer | Sale 10b5-1 | −12,941 | $25.16 | $326K | 105,341 |
| 2026-04-23 | Cross Shawn Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,941 | 150,000 | ||
| 2026-04-22 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 | +1,500 | $16.45 | $25K | 106,841 |
| 2026-04-22 | Cross Shawn Chief Financial Officer | Sale 10b5-1 | −1,500 | $25.01 | $38K | 105,341 |
| 2026-04-22 | Cross Shawn Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,500 | 162,941 | ||
| 2026-04-21 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 | +2,845 | $16.45 | $47K | 108,186 |
| 2026-04-21 | Cross Shawn Chief Financial Officer | Sale 10b5-1 | −2,845 | $25.01 | $71K | 105,341 |
| 2026-04-21 | Cross Shawn Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,845 | 164,441 | ||
| 2026-04-20 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 | +7,714 | $16.45 | $127K | 113,055 |
| 2026-04-20 | Cross Shawn Chief Financial Officer | Sale 10b5-1 | −7,714 | $25.14 | $194K | 105,341 |
| 2026-04-20 | Cross Shawn Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,714 | 167,286 | ||
| 2026-03-17 | SLONIN JONATHAN Chief Medical Officer | Sale 10b5-1 | −3,261 | $22.82 | $74K | 223,640.18 |
| 2026-03-17 | Froimson Mark Director | Sale | −500 | $21.81 | $11K | 20,136 |
| 2026-02-11 | Cross Shawn Chief Financial Officer | Grant or award | +49,091 | 105,341 |
Page 2 of 9 · 161 trades